Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Electric eye therapy: can a home device slow blindness?

NCT ID NCT07531927

Disease control Sponsor: Okuvision GmbH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times

Summary

This study tests if a device that delivers mild electrical pulses to the eye (transcorneal electrical stimulation) can safely slow the progression of geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. About 70 people aged 60 and older will use the device at home for 30 minutes once a week for a year. The study compares two different types of electrical stimulation against a sham (placebo) treatment to see which works best.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Willing and able to understand the study and provide informed consent * 60 years of age or older * Diagnosis of geographic atrophy due to age-related macular degeneration confirmed by imaging * The affected area in the eye must be within a defined size range and clearly visible on imaging * Eye conditions must allow for good-quality images and reliable measurements * Must have a minimum level of visual acuity * Women of childbearing potential must have a negative pregnancy test, and must agree to use effective contraception during the study (women who are postmenopausal or surgically sterile are not subject to pregnancy-related requirements) Exclusion criteria: * History or presence of certain eye conditions (e.g. macular edema, abnormal blood vessel growth or related conditions, retinal detachment, blood vessel blockage) in the study eye * Previous major eye surgeries (including retinal surgery or vitrectomy) * Previous laser treatment or injections in the study eye * Any other eye condition that could interfere with vision tests, imaging or study results * Planned eye surgery during the study period * Recent treatment with investigational drugs for geographic atrophy * Presence of active medical implants * Serious or uncontrolled systemic diseases, history of epilepsy or poor general health or conditions affecting the ability to follow study procedures * Participation in another clinical study recently or at the same time * Breastfeeding, relevant allergies (e.g. to silver), or heavy smoking

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Geographic atrophy secondary to age-related macular degeneration are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

age-related macular degeneration Geographic Atrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Geographic atrophy secondary to age-related macular degeneration

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    5 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Centre for Ophthalmology, University Hospital Tuebingen

    RECRUITING

    Tübingen, 72076, Germany

  • Department of Ophthalmology, Klinikum Stuttgart

    RECRUITING

    Stuttgart, 70174, Germany

  • Department of Ophthalmology, Ludwig-Maximilians-University Munich

    RECRUITING

    München, 80336, Germany

  • Department of Ophthalmology, University Hospital Ulm

    NOT_YET_RECRUITING

    Ulm, 89075, Germany

  • Department of Ophthalmology, University Medical Center Hamburg-Eppendorf

    RECRUITING

    Hamburg, 20246, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.